The article presents the results of the clinical use of Roncoleukin®
(recombinant interleukin-2) and Viferon® (interferon alfa-2b) in the complex
treatment of more than 300 patients with COVID-19 in outpatient and inpatient
conditions from May to December 2020 in various regions of Russia and abroad.
The obtained results indicate a dramatic improvement in the condition of
patients with the inclusion of Roncoleukin® and Viferon® in the COVID-19
treatment regimen, which made it possible to achieve patient recovery in all
cases and avoid death among patients with severe COVID-19. The article justifies
the necessity of compulsory use of interleukin-2 and interferon alpha-2b in the
treatment regimen of COVID-19 patients as the factors determining the timely
activation of specific immune responses that block the growth of nonspecific
immune reactions leading to the generalization of infectious and inflammatory
processes (“cytokine storm”), decompensation of chronic diseases and death.
The need to normalize the psychoemotional state as an important pathogenetically
significant factor that has a considerable impact on both the course of
coronavirus disease and its outcome is demonstrated.